WC
ASMB icon

Wexford Capital’s Assembly Biosciences ASMB Stock Holding History

Wexford Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-554
Closed -$40K – 204
2020
Q4 		$40K Buy
+554
New +$65K 0.01% 240

Other funds holding ASMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wexford Capital's ASMB Position: Q1 2021 in Review

Wexford Capital sold out of Assembly Biosciences (ASMB) in Q1 2021, closing a stake of 554 shares — an estimated $40K sold.

Wexford Capital first reported a position in ASMB in Q4 2020 and held it in 1 quarter. The position peaked at $40K in Q4 2020. 107 funds tracked by Wall St. Rank hold ASMB as of Q1 2021.

  • Wexford Capital reported no remaining Assembly Biosciences position as of Q1 2021 after selling out during the quarter.
  • Wexford Capital sold 554 Assembly Biosciences shares in Q1 2021, an estimated $40K.
  • Wexford Capital first reported a position in Assembly Biosciences in Q4 2020 and held it in 1 quarter.
  • Wexford Capital's Assembly Biosciences position peaked at $40K in Q4 2020.
  • 107 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.